Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

P. Pradère; C. Boutros; J. Y. Scoazec; P. Dorfmüller; F. Leroy-Ladurie; D. Boulate; J. Le Pavec; C. Robert

doi:10.1016/j.ejca.2017.12.013

Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

P. Pradère, C. Boutros, J. Y. Scoazec, P. Dorfmüller, F. Leroy-Ladurie, D. Boulate, J. Le Pavec, C. Robert

Research output: Contribution to journal › Letter › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	144-146
Number of pages	3
Journal	European Journal of Cancer
Volume	93
DOIs	https://doi.org/10.1016/j.ejca.2017.12.013
Publication status	Published - 1 Apr 2018

Access to Document

10.1016/j.ejca.2017.12.013

Cite this

@article{38b7c9e4d82148a4b8e8d5074af6b30d,

title = "Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?",

author = "P. Prad{\`e}re and C. Boutros and Scoazec, {J. Y.} and P. Dorfm{\"u}ller and F. Leroy-Ladurie and D. Boulate and {Le Pavec}, J. and C. Robert",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.ejca.2017.12.013",

language = "English",

volume = "93",

pages = "144--146",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Pulmonary nodules and immunotherapy

T2 - disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

AU - Pradère, P.

AU - Boutros, C.

AU - Scoazec, J. Y.

AU - Dorfmüller, P.

AU - Leroy-Ladurie, F.

AU - Boulate, D.

AU - Le Pavec, J.

AU - Robert, C.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85041574710&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.12.013

DO - 10.1016/j.ejca.2017.12.013

M3 - Letter

C2 - 29402507

AN - SCOPUS:85041574710

SN - 0959-8049

VL - 93

SP - 144

EP - 146

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

Access to Document

Other files and links

Cite this